SML4332

Lifitegrast sodium

≥98% (HPLC)

• Synonim(y): N-​[[2-​(6-Bbenzofuranylcarbonyl​)​-​5,​7-​dichloro-​1,​2,​3,​4-​tetrahydro-​6-​isoquinolinyl]​carbonyl]​-​3-​(methylsulfonyl)​-L-​phenylalanine sodium salt, SAR 1118 sodium
• Wzór empiryczny (zapis Hilla): C₂₉H₂₃Cl₂N₂NaO₇S
• Numer CAS: 1119276-80-0
• Masa cząsteczkowa: 637.46
• UNSPSC Code: 12352200
• Assay: ≥98% (HPLC)
• Form: powder
• Storage condition: desiccated

Właściwości

• Quality Segment: 100
• assay: ≥98% (HPLC)
• form: powder
• storage condition: desiccated
• color: white to beige
• solubility: DMSO: 2 mg/mL, clear
• storage temp.: -10 to -25°C

Opis

Biochem/physiol Actions

Lifitegrast, a potent LFA-1 antagonist (IC50 ~2.98 nM), treats Dry Eye Disease by inhibiting T-cell mediated inflammation. It competitively and rapidly binds LFA-1 on T-lymphocytes, blocking interaction with ICAM-1, which inhibits crucial inflammatory processes like T-cell adhesion, migration, activation, and pro-inflammatory cytokine release (e.g., IFN-γ, TNF-α). This action downregulates T-cell activation signaling and inflammatory gene expression, producing targeted anti-inflammatory effects. Administered topically, Lifitegrast exhibits high ocular retention and bioavailability, ensuring localized biological action with minimal systemic exposure.

Disclaimer

Hygroscopic Store with desiccant

Ta strona może zawierać tekst przetłumaczony maszynowo.

Informacja o środkach bezpieczeństwa

• Klasa składowania: 11 - Combustible Solids